Immuneering is selling 18,959,914 shares at $9.23 and expects about $164.1 million in net proceeds, plus about $23.3 million from a Sanofi unit. The company's 2024 audit report carried a going-concern paragraph.
Latest Immuneering news
We have not published a story on Immuneering yet. When there is news, it will appear here.
Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.
Questions about Immuneering
Has Immuneering issued a going-concern warning?
Our latest story on this, dated Sep 24, 2025: "Immuneering prices offering at $9.23 a share; Sanofi unit to buy $25.0 million". The story links the filing or release it is based on. Read the story.
Has Immuneering raised money recently?
Our latest story on this, dated Sep 24, 2025: "Immuneering prices offering at $9.23 a share; Sanofi unit to buy $25.0 million". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Immuneering?
Immuneering Corporation trades under the ticker IMRX on NASDAQ.
Where is Immuneering listed?
Immuneering Corporation is listed on NASDAQ.
What is the SEC CIK of Immuneering?
The SEC Central Index Key (CIK) for Immuneering Corporation is 1790340. Its filings are on SEC EDGAR.
How many shares does Immuneering have outstanding?
25,938,064 shares as of 2021-09-03, per the cover page of its 10-Q filed 2021-09-09.
Which country or territory is Immuneering listed under?
Our directory records Immuneering Corporation under United States.
What does Immuneering do?
Our directory classifies Immuneering Corporation as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of Immuneering?
The ISIN recorded for Immuneering Corporation is US45254E1073.
Does aibio.space cover Immuneering?
aibio.space lists Immuneering Corporation among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Immuneering incorporated?
SEC records list its state or country of incorporation as DE.
Is Immuneering profitable?
Immuneering Corporation reported a net loss of $56.0 million for the fiscal year ended Dec 31, 2025, and used $45.3 million of cash in operations, per its annual report to the SEC.
How much does Immuneering spend on research and development?
$42.0 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does Immuneering have?
$58.2 million in cash at Sep 30, 2026, per its 10-Q.
What is the latest Immuneering (IMRX) stock news?
Our latest story on Immuneering, dated Sep 24, 2025: "Immuneering prices offering at $9.23 a share; Sanofi unit to buy $25.0 million". Immuneering is selling 18,959,914 shares at $9.23 and expects about $164.1 million in net proceeds, plus about $23.3 million from a Sanofi unit. The company's 2024 audit report carried a going-concern paragraph. Source.
Investor discussion: Immuneering
Members talk about Immuneering (IMRX). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Capital-markets timeline
Financings, listing notices, splits, legal actions and other investor events at Immuneering, newest first. Each line links the filing it comes from.
Financings
Reported a financing. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). Source
Financings
Reported a financing. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). Source
Financings
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Financings
Set up an at-the-market program to sell shares over time. SEC Form 424B5. Source
Financings
Set up an at-the-market program to sell shares over time. SEC Form 424B5. Source
Financings
Reported a financing. SEC Form 8-K (Items 8.01). Source
Distress
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. Source
Stock chart
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:IMRX on TradingView.
SEC filings and registration
SEC name
Immuneering Corp
CIK
1790340
Industry (SIC)
Pharmaceutical Preparations (2834)
US tickers
IMRX (Nasdaq)
State or country of incorporation
DE
Fiscal year ends
December 31
Filer category
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Business address
245 MAIN STREET, SECOND FLOOR, CAMBRIDGE, MA, 02142
Phone
617-500-8080
Shares outstanding
25,938,064 as of 2021-09-03 (10-Q filed 2021-09-09)
Recent filings (8-K and 6-K are the company's own announcements)
Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.
Listing details
Immuneering Corporation is a public biotech or pharmaceutical company listed on NASDAQ under the ticker IMRX, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio